Jem Thompson, PhD
LightNews LightNews
jemimathompson.bsky.social
Jem Thompson, PhD
@jemimathompson.bsky.social
30 followers 32 following 9 posts
Research Fellow in Trial Conduct Methodology at MRC Clinical Trials Unit at UCL.
Posts Replies Media Videos
Reposted by Jem Thompson, PhD
innovative-ctu.bsky.social
Young people living with HIV manage their condition better when their antiretroviral therapy is given by injections every eight weeks, rather than in the form of daily tablets, according to results from the LATA trial

www.innovative-ctu.ucl.ac.uk/news/news-st...
HIV injections work better than tablets for young people | UCL Innovative Clinical Trials Unit
www.innovative-ctu.ucl.ac.uk
September 18, 2026 at 7:45 AM
Reposted by Jem Thompson, PhD
innovative-ctu.bsky.social
📢 Heading to Birmingham for #ICTMC2026?

Our #ClinicalTrials methodology researchers will be presenting talks, posters and workshops throughout the conference.

🔗 View the full schedule and find out where to meet the team: www.innovative-ctu.ucl.ac.uk/news/news-st...
Innovative Clinical Trials Unit at ICTMC 2026 Oral presentations Tuesday 15 September Missing data and infographics. 10:45-12PM (BST). Missing viral load measurments in HIV treatment trials: a comparison of approaches (Tra My Pham) Wednesday 16 September Conduct- Data-enabled trials. 3:45-5PM (BST). Streamlining event ascertainment from health systems data: accuracy of the SCORE-CVD myocardial infraction phenotyping algorithm in a prostate cancer trial (Sharon Love, Macey Murray) 3:45-5PM (BST). Health systems data for evaluating mortality outcomes in randomised prostate cancer trials: A data utility comparison study within the STAMPEDE and PATCH trials (Grisma Patel) Conduct-Trial management, trial monitoring and quality control. 3:45-5PM (BST). Smarter Processes for Enhanced Clinical TRial Efficiency (SPECTRE): Identifying Inefficiencies in site set-up (Aaron horsey) Analysis - Borrowing of information. 1:45-2:45PM (BST). A comparison of different information-borrowing approaches in a trial evaluating dolutegravir-based antiretroviral therapy in HIV-infected children (Wenyue Li) Innovative Clinical Trials Unit at ICTMC 2026 Oral presentations Thursday 17 September Design-Adaptive and innovative designs. 10:40-11:40AM (BST): Recommendation-wise type 1 error: a new measure for clinical trials using Bayesian borrowing for precision medicine (Ian White) Analysis-Data-enabled trials and secondary data. 10:40-11:40AM (BST). The need for fully effective federated analytics of data sources of clinical trials (Stella Fabiane) Innovative Clinical Trials Unit at ICTMC 2026 Posters COSSMaT Study- Core Outcome Set for Severe Malaria Treatment Trials - Gideon Asamoah From Paperwork to Partnership: A Collaborative and Risk-Proportionate Approach to Trial Database Development - Lindsey Masters Emulating a randomised controlled trial based on the ODYSSEY trial design using paediatric HIV cohort data - Jerome Johnson Measurement and reporting of menstrual blood loss outcomes in clinical trials which assess heavy menstrual bleeding: a comprehensive review - Lily Nicholson Understanding the current state of knowledge around using Health Systems Data in clinical trials - Macey Murray Assessing the utility of routinely collected Health Systems Data and Case Report Form data in Randomised Controlled Trials: A Systematic Review of DUCkS - Grisma Patel Evidence‑Informed Consent Guidance for Trustworthy Access to Health Systems Data for Trials (CrossWord): Insights from a multistakeholder collaborative approach - Kate Roberts
September 10, 2026 at 8:39 AM
Reposted by Jem Thompson, PhD
innovative-ctu.bsky.social
📢 We're hiring!

We are looking for a Science Communications Officer (maternity cover).

A varied role creating content that showcases the impact of national & international trials in cancer, Parkinson's disease, paediatric HIV, multiple sclerosis & more.

📅 Apply by 10 Sept 2026

🔗 buff.ly/sdYteSn
UCL – University College London
UCL is consistently ranked as one of the top ten universities in the world (QS World University Rankings 2010-2022) and is No.2 in the UK for research power (Research Excellence Framework 2021).
www.ucl.ac.uk
August 24, 2026 at 1:16 PM
Reposted by Jem Thompson, PhD
innovative-ctu.bsky.social
Working in clinical trials and want to make better use of routinely collected healthcare data?

Learn how to compare datasets and assess their suitability for specific research questions at our upcoming DUCks workshop.

📅 22 Oct 2026, 10-1 (UK time)

🔗 More information: bit.ly/3RHiUQf
Flyer DUCkS workshop Thur 22 October 2026 10-1 (UK time) In person - 90 High Holborn, London More info/registration: QR code
August 11, 2026 at 1:56 PM
Reposted by Jem Thompson, PhD
innovative-ctu.bsky.social
What is getting in the way of efficient safety reporting in UK clinical trials?

Our latest study shares insights from Clinical Trials Unit staff and includes recommendations for improving safety reporting practices.

🔗 journals.plos.org/plosone/arti...
Walking the tightrope of justifiable decision‑making: An exploratory qualitative study identifying barriers and solutions to efficient safety reporting
Background Safety reporting is integral to clinical trial conduct, aiming to protect the rights and safety of trial participants and future patients. Over time, reporting safety events has become incr...
journals.plos.org
August 6, 2026 at 2:14 PM
Reposted by Jem Thompson, PhD
innovative-ctu.bsky.social
📈 News from the RAMPART trial!

Results presented at #ASCO26 show that using the immunotherapy drug durvalumab alone does not lower the risk of kidney cancer coming back after surgery compared with active monitoring.

🔗 Read more: www.innovative-ctu.ucl.ac.uk/news/news-st...
Using two immunotherapy drugs together benefits people with kidney cancer | UCL Innovative Clinical Trials Unit
www.innovative-ctu.ucl.ac.uk
June 2, 2026 at 10:25 AM
Reposted by Jem Thompson, PhD
innovative-ctu.bsky.social
Today is #InternationalClinicalTrialsDay 🌍

Patients and the public are at the heart of our research. Our #PPI group helps shape our trials, making them better, more relevant, and more inclusive.

Today we’re asking our patient reps: What are you #ProudestOf in your work as part of the PPI group?
A quote from Ben, it reads "I am proud of the work our PPI group has done in providing training and support to new PPI representatives and researchers, helping to maximise the impact of PPI in every study. The rapid and innovative response to the need for PPI in COVID research, by developing the concept of a PPI panel, is another great achievement that is now being applied in other disease areas, such as TB." A quote from Danielle, it reads "I am proudest of my involvement in promoting the use of the patient information sheet (PIS) developed by Dr Peter Knapp, ever since it was first presented at the INVOLVE conference. As a founder member of the Paediatric Oncology Reference Team (PORT), I made sure we adopted it for paediatric oncology trials. This made a significant difference for PORT, as we could make the PIS much more accessible. This is especially important with some children’s cancers, where Day 1 randomisation means families have very little time to get their head around things before making a decision for their child." A quote from Ian, it reads "I am proud of our contribution to the success of clinical trials through our provision of advice for the Quality Management Advisory Group. We know it has made a positive difference to the studies in the eyes of the project PPI leads, who feel the review of documents has been excellent. The comments we provide prompt interesting discussions within the trial teams, leading to improvements in PPI processes." A quote from Virginia, it reads "I’m proudest of the contribution we make to helping studies become easier for everyone to read and understand. Through PPI, we also encourage researchers to think about the real, practical realities of running a study and how best to involve participants. That’s where we really see the difference we make!"
May 20, 2026 at 9:18 AM
Reposted by Jem Thompson, PhD
innovative-ctu.bsky.social
It’s Wednesday, and we’re back with another #ProudestOf moment from the Unit!

This week, we celebrate Jemima Thomson, Research Fellow and proud member of the ICTM Education team.

We asked Jem what she’s #ProudestOf in her work at the Unit. Here’s what she shared 👇
A card with a quote from Jem. It reads “The thing I’m proudest of about the unit’s work is the dedication and hard work that goes into innovation and improving how clinical trials are conducted. Striving to make trial conduct more efficient benefits everyone, especially trial participants and patients who may benefit from treatments in the future. In my own work, I am most proud of my contribution to education. The students we teach are the trialists of the future. I think that having the opportunity to learn from specialists in the field is inspiring. I am always learning!”
April 1, 2026 at 11:01 AM
jemimathompson.bsky.social
Our new paper shows that reporting of the use of routine data on trial results publications is improving, but there is still work to to be done! #HSD #RoutineData #ClinicalTrials
innovative-ctu.bsky.social UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · Dec 4
🆕New publication alert!

Our latest systematic review of trials using Health Systems Data (HSD) shows that, although reporting has improved over time, it still falls short of CONSORT-ROUTINE guidelines.

It includes 3 key recommendations 👇
Text reading: "Key recommendations: 1- Funders should make trial teams aware of CONSORT-ROUTINE expectations to guide design, funding allocation, and timing of HSD access applications. 2- Journal editors could incorporate CONSORT-ROUTINE into author instructions to support clearer reporting. 3- Authors would benefit from more detailed guidance and examples—an update to CONSORT-ROUTINE could make data collection and reporting more efficient and reliable."
December 4, 2025 at 1:47 PM
Reposted by Jem Thompson, PhD
aarononops.bsky.social
Trials aim to make treatments better.

But do trials themselves get better as they go?

Continuous improvement isn’t corporate fluff. It’s the difference between a drug reaching patients this year… or next.

aaronsopslog.wordpress.com/2025/10/03/a...
Application of Continuous Improvement in Clinical Trials
Clinical trials exist to shorten the distance between today’s treatment and tomorrow’s better one. They are, at their core, exercises in continuous improvement. Every protocol is written to nudge m…
aaronsopslog.wordpress.com
October 3, 2025 at 8:02 AM
jemimathompson.bsky.social
Do you work in #ClinicalTrials ?

We want to improve the use of Health Systems Data (real-world data containing info about healthcare interactions).

Complete this short survey and enter our prize draw. Approved by the UCL Ethics committee [project ID 1967]

forms.office.com/e/kpXsyZdjWX
forms.office
September 24, 2025 at 2:01 PM
Reposted by Jem Thompson, PhD
aarononops.bsky.social
Getting clinical trials greenlit is harder than it should be. Contracts, IMP, radiation assurance… It's all very important. However, a major issue is study designs that forget what’s realistic for sites and for patients.

I’ve shared a few ideas: aaronsopslog.wordpress.com/2025/09/19/g...
Getting to Greenlight: How Can We Activate Clinical Trials, Fast?
The process of bringing a clinical trial site from expression of interest to first patient in is often summed up in one word – greenlight. It’s the moment when a hospital or research unit is …
aaronsopslog.wordpress.com
September 19, 2025 at 8:04 AM
Reposted by Jem Thompson, PhD
aarononops.bsky.social
Site Initiation Visits shouldn’t just be box-ticking.
My latest post: moving past slide decks, modular training, and turning SIVs into genuine conversations.
🔗 aaronsopslog.wordpress.com/2025/09/12/b...
Beyond the Tick-Box: Making the Most of SIVs
Site Initiation Visits (SIVs) are meant to set the tone for how a trial will run. Too often, they risk becoming a box-ticking exercise: a slide deck is read out, attendees nod politely, and everyon…
aaronsopslog.wordpress.com
September 12, 2025 at 7:41 AM
Reposted by Jem Thompson, PhD
aarononops.bsky.social
Are we ready? Trial success depends on more than opening sites. First, there's site evaluation and feasibility = capacity, capability, and commitment.
aaronsopslog.wordpress.com?p=110
September 5, 2025 at 11:23 AM
Reposted by Jem Thompson, PhD
innovative-ctu.bsky.social
Midweek already? Let’s celebrate another #ProudestOf moment from our brilliant team at the Unit!

This week, we’re hearing from Annabelle South (@annabellesouth.bsky.social), Principal Research Fellow: Research Impact & Communication.

She reflects on what she’s #ProudestOf in her work at the Unit👇
A card with a quote from Annabelle South, it reads “The thing I’m proudest of in my own work at the Unit is the results of the Show RESPECT study (which looked at how to communicate results to trial participants) influencing HRA and trial funders’ guidance – this will hopefully help ensure that people who take part in trials get access to the results of those trials.”
August 20, 2025 at 8:17 AM
Reposted by Jem Thompson, PhD
spectre-ctops.bsky.social
Make sure to see our very own @jemimathompson.bsky.social at the #UKTMNconference today to talk about site setup process mapping 🗺️
jemimathompson.bsky.social Jem Thompson, PhD @jemimathompson.bsky.social · Jun 3
@spectre-ctops.bsky.social Come and visit me at 12.25 to talk about the SPECTRE project: Poster 5!!
#UKTMNconference #MRCCTU
Poster with graphs and sample process map for the Spectre project at MRC clinical trials unit
June 3, 2025 at 8:14 AM
jemimathompson.bsky.social
@spectre-ctops.bsky.social Come and visit me at 12.25 to talk about the SPECTRE project: Poster 5!!
#UKTMNconference #MRCCTU
Poster with graphs and sample process map for the Spectre project at MRC clinical trials unit
June 3, 2025 at 8:09 AM
jemimathompson.bsky.social
Ready for a packed day of talks and my poster presentation for #SPECTRE at the #UKTMNconference @spectre-ctops.bsky.social @mrcctu.bsky.social
June 3, 2025 at 8:07 AM
Reposted by Jem Thompson, PhD
innovative-ctu.bsky.social
"Every person that joins any trial is a hero."

Former colleague Matt Sydes, who has dedicated his career to designing, running, analysing, and improving #ClinicalTrials, shares a powerful personal story about his son's involvement in a clinical trial.

@mattsydes.bsky.social

Read the full story 👇
May 21, 2025 at 8:52 AM
jemimathompson.bsky.social
Tiring but fun day at volunteering at May-hem. Over 6,000 Rainbows, Brownies, Guides, Rangers, Young Leaders and their Leaders attended… I think mayhem sums it up pretty well!
May 10, 2025 at 5:58 PM